ASX Announcement
18 November 2026

Proposed Merger with Genetic Signatures Limited not proceeding

Microba Life Sciences Limited (ASX: MAP) ("**Microba**" or "the **Company**") refers to previous announcements relating to the proposed merger between Genetic Signatures Limited (ASX: GSS) (**GSS**) and Microba (**Proposed Merger**) as well as Microba's request for a voluntary suspension of trading in its securities on 17 November 2026 while it explores funding options.

Unfortunately, as announced by GSS today, GSS has resolved not to proceed with the Proposed Merger in light of Microba's announcement that it will not have financial capacity to complete the Proposed Merger without additional capital. The Proposed Merger will therefore not proceed.

The requirement for additional capital was a result of Tranche 2 of Microba's institutional placement, announced to the ASX on 20 October 2026 (**Placement**) not being able to proceed on the basis that revisions to the indicative terms of the Proposed Merger, while considered generally commercially acceptable to the Microba Board, were such that Microba could not satisfy the conditions to the Placement.

This is a disappointing outcome as it follows many months of discussions, engagement and due diligence and Microba had been working on options to obtain alternative funding.

Notwithstanding that the Proposed Merger is not progressing, Microba is continuing to assess its cashflow position and is exploring its options for funding whilst it remains in voluntary suspension.

This announcement has been authorised for release by the Board of Directors.

About Microba Life Sciences Limited
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com